# "E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"

> **NCT02957630** · PHASE1,PHASE2 · COMPLETED · sponsor: **Estetra** · enrollment: 101 (actual)

## Conditions studied

- Contraception
- Liver Metabolism
- Hemostasis Parameter

## Interventions

- **DRUG:** 15 mg E4/3 mg DRSP
- **DRUG:** 30 mcg EE/150 mcg LNG
- **DRUG:** 20 mcg EE/3 mg DRSP

## Key facts

- **NCT ID:** NCT02957630
- **Lead sponsor:** Estetra
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2017-10-09
- **Final completion:** 2017-10-09
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2018-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02957630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02957630, ""E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02957630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*